Upstream Bio, INC

Upstream Bio reported second quarter 2026 financial results and business updates, highlighting progress in its verekitug development for severe inflammatory respiratory diseases and a cash runway through 2027.

Upstream Bio, Inc. announced the results of its 2026 Annual Meeting of Stockholders, confirming the election of two Class II directors and the ratification of PricewaterhouseCoopers LLP as its independent auditor.

Upstream Bio announced first quarter 2026 financial results, highlighting progress in its Phase 3 programs for severe asthma and CRSwNP, while adjusting its COPD trial enrollment.

Upstream Bio, Inc. has entered into a sales agreement with Leerink Partners LLC to potentially sell up to $150 million of its common stock through an at-the-market offering.

Upstream Bio announced its Phase 3 development strategy for verekitug in severe asthma and CRSwNP, alongside its fourth quarter and full year 2025 financial results.

Upstream Bio announced positive top-line results from its Phase 2 VALIANT clinical trial for verekitug in severe asthma, meeting its primary endpoint.

Upstream Bio, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing clinical trial progress for its lead candidate, verekitug, while reporting continued net losses and a substantial accumulated deficit.

Upstream Bio, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing continued investment in its lead drug candidate, verekitug, and reporting a net loss.

Upstream Bio, a clinical-stage biopharmaceutical company, reported positive top-line results for verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) and advanced its severe asthma and COPD programs, while incurring increased net losses.

Upstream Bio reports significant progress in its verekitug clinical programs for severe asthma, CRSwNP, and COPD, with sufficient cash to fund operations through 2027.

Upstream Bio's Q1 2025 results show increased R&D spending as the company advances its verekitug clinical trials, with topline CRSwNP data expected in Q3 2025 and asthma data in H1 2026.

Upstream Bio, a clinical-stage biopharmaceutical company, released its third quarter 2024 financial results, highlighting ongoing clinical trials and financial activities.

Upstream Bio's 10-K filing highlights the company's dedication to developing Verekitug, a novel treatment for inflammatory diseases, particularly severe respiratory disorders.

Upstream Bio, Inc. CFO and COO Michael Gray reported a sale of 853 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Everett Rand, CEO of Upstream Bio, Inc., reported the sale of 2,095 shares of common stock on June 16, 2026, to cover tax withholding obligations related to restricted stock unit vesting.

Upstream Bio, Inc. officer Adam Houghton sold 700 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Upstream Bio's Chief Medical Officer, Aaron Deykin, sold 895 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Upstream Bio, Inc. reports that General Counsel Allison Ambrose sold 477 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Director Marcella K. Ruddy was granted 17,096 stock options in Upstream Bio, Inc. as part of standard equity compensation.

Upstream Bio, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 9, 2026.

Upstream Bio, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Upstream Bio, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 10, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Upstream Bio increases its IPO size by registering an additional 2,875,000 shares of common stock.

Upstream Bio, a clinical-stage biotech firm, is set to launch its initial public offering, aiming to raise $190 million to advance its verekitug program targeting severe respiratory and inflammatory diseases.

Upstream Bio, a clinical-stage biotech firm, has filed an S-1 registration statement for an initial public offering to further develop its treatments for inflammatory diseases, particularly severe respiratory disorders.

Norges Bank has reported a beneficial ownership of 7.73% in Upstream Bio, Inc., holding 4,206,586 shares as of June 30, 2026.

BlackRock, Inc. has reported beneficial ownership of 5.2% of Upstream Bio Inc.'s common stock as of June 30, 2026.

Decheng Capital Global Life Sciences Fund IV, L.P. has reported a 5% beneficial ownership stake in Upstream Bio, Inc. common stock.

TCG Crossover Fund I, L.P., TCG Crossover GP I, LLC, and Chen Yu have reported a combined beneficial ownership of 3.9% in Upstream Bio, Inc. common stock.

HBM Healthcare Investments (Cayman) Ltd. has reported a 4.1% beneficial ownership stake in Upstream Bio, Inc. as of September 30, 2025.

Norges Bank, acting on behalf of the Government of Norway, has reported a 5.3% passive ownership stake in Upstream Bio Inc.